


## PHARMACEUTICAL 2021

## Citius Pharmaceuticals Inc. Rank 150 of 402







## PHARMACEUTICAL 2021

## Citius Pharmaceuticals Inc. Rank 150 of 402

The relative strengths and weaknesses of Citius Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Citius Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Citius Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 102% points above the market average of 47%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 13,982               |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 9,347                |
| Liabilities, Current                        | 4,097                |
| Liabilities, Non-Current                    | 855                  |
| Other Assets                                | 20,443               |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 803                  |
| Other Liabilities                           | 5,150                |
| Other Net Income                            | 163                  |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 1.6                  |
| Research and Development                    | 8,813                |
| Selling, General and Administrative Expense | 8,095                |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 43,774               |
| Liabilities              | 10,103               |
| Expenses                 | 17,711               |
| Revenues                 | 0                    |
| Stockholders Equity      | 33,671               |
| Net Income               | -17,548              |
| Comprehensive Net Income | -17,548              |
| Economic Capital Ratio   | 150%                 |

